Patient tumor samples will be tested using a common panel of genes agreed upon by all centers. Test results will rely upon common pipelines for alignment, analysis, and variant calling; common controls will ensure genomic data is high-quality and uniform.

Ultimately, these molecular diagnostic methodologies will be used to define clinical groups to determine appropriate therapies.

Objectives

Cross-validate panel of molecular markers available within Cancer Core Europe to ensure results are robust, high-quality, and uniform across centers.